- Home
- ATNI vs DBVT Comparison
ATNI vs DBVT Comparison
Compare ATNI & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNI
- DBVT
- Stock Information
- Founded
- ATNI 1987
- DBVT 2002
- Country
- ATNI United States
- DBVT France
- Employees
- ATNI N/A
- DBVT N/A
- Industry
- ATNI Telecommunications Equipment
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATNI Telecommunications
- DBVT Health Care
- Exchange
- ATNI Nasdaq
- DBVT Nasdaq
- Market Cap
- ATNI 242.7M
- DBVT 273.6M
- IPO Year
- ATNI 1991
- DBVT N/A
- Fundamental
- Price
- ATNI $15.75
- DBVT $9.38
- Analyst Decision
- ATNI Strong Buy
- DBVT Buy
- Analyst Count
- ATNI 1
- DBVT 4
- Target Price
- ATNI $30.00
- DBVT $14.81
- AVG Volume (30 Days)
- ATNI 36.3K
- DBVT 35.3K
- Earning Date
- ATNI 10-28-2025
- DBVT 07-29-2025
- Dividend Yield
- ATNI 6.47%
- DBVT N/A
- EPS Growth
- ATNI N/A
- DBVT N/A
- EPS
- ATNI N/A
- DBVT N/A
- Revenue
- ATNI $719,593,000.00
- DBVT $3,800,000.00
- Revenue This Year
- ATNI $1.65
- DBVT $1,743.46
- Revenue Next Year
- ATNI $1.59
- DBVT $1,045.66
- P/E Ratio
- ATNI N/A
- DBVT N/A
- Revenue Growth
- ATNI N/A
- DBVT N/A
- 52 Week Low
- ATNI $13.76
- DBVT $2.21
- 52 Week High
- ATNI $33.72
- DBVT $12.78
- Technical
- Relative Strength Index (RSI)
- ATNI 45.86
- DBVT 42.14
- Support Level
- ATNI $15.49
- DBVT $8.91
- Resistance Level
- ATNI $17.12
- DBVT $10.34
- Average True Range (ATR)
- ATNI 0.77
- DBVT 0.51
- MACD
- ATNI 0.08
- DBVT -0.05
- Stochastic Oscillator
- ATNI 47.58
- DBVT 18.74
About ATNI ATN International Inc.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.